What is Comparative Biosciences?
Comparative Biosciences, Inc. (CBI) is a specialized provider of preclinical toxicology and pharmacokinetics services, catering to the biomedical and biopharmaceutical industries. The company offers comprehensive efficacy studies across diverse therapeutic areas, including dermatology, ophthalmology, oncology, and cardiovascular diseases. CBI operates with high research standards, evidenced by its AAALAC accreditation and registration with regulatory bodies like the FDA and USDA. Its core mission is to accelerate drug discovery programs, supporting clients from initial target identification through to the management of clinical trials.
How much funding has Comparative Biosciences raised?
Comparative Biosciences has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Comparative Biosciences
PPP
Public-Private Partnership
What's next for Comparative Biosciences?
With its large-scale, late-stage funding context, Comparative Biosciences is poised for significant expansion and enhancement of its service offerings. This strategic investment will likely fuel advancements in its preclinical research capabilities, potentially broadening its therapeutic area focus or investing in cutting-edge technologies for toxicology and pharmacokinetics. The company's commitment to regulatory compliance and quality assurance suggests a trajectory aimed at solidifying its role as a key partner for biopharmaceutical firms navigating the complex drug development pipeline.
See full Comparative Biosciences company page
